Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Halazepam is a benzodiazepine derivative that was used primarily as an anxiolytic to relieve anxiety, nervousness, and tension associated with anxiety disorders. It exerts its effects by acting as a positive allosteric modulator of the GABA(A) receptor complex in the central nervous system, enhancing the inhibitory effect of gamma-aminobutyric acid (GABA). Halazepam also has anticonvulsant, sedative, and muscle relaxant properties. It was considered less toxic than chlordiazepoxide or diazepam. The drug was invented by Schlesinger Walter in the United States and marketed from 1981 under various brand names including Paxipam (US), Alapryl (Spain), and Pacinone (Portugal). However, it is no longer commercially available in the United States after being withdrawn for poor sales by its manufacturer Schering in 2009[2][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on halazepam.